Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Maxim Group Downgrades Kintara Therapeutics to Hold

Maxim Group analyst Jason McCarthy downgrades Kintara Therapeutics (NASDAQ:KTRA) from Buy to Hold.
byBenzinga Newsdesk
September 29, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Maxim Group analyst Jason McCarthy downgrades Kintara Therapeutics (NASDAQ:KTRA) from Buy to Hold.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Tesla’s Full Self Driving To Pinch Pockets, Raoul Paul Shrugs Off Crypto Selloff, Rivian CEO’s 10-Figure Paycheck: 5 Key Stories You May Have Missed From The Weekend

By Shanthi Rexaline
August 22, 8:35 AM
As earnings wind down and investors look ahead to a catalyst-starved near term, with volatility likely to be the order of the day in the market. Market momentum has stalled following the run-up seen since mid-June. Here's a recap of a few major headlines that hit the wire over the weekend, which could provide trading cues:

AAPL